

Table S1. Patient and graft characteristics of Treg and 108 historical control patients			
	Treg	Historical Controls	p-value
Number of patients	23	108	NA
Age in years Median (range)	52 (25–68)	51 (6-69)	.18
Weight in kg Median (range)	77 (50–133)	79 (22-145)	.54
TNC ($\times 10^7/\text{kg}$) Median (range)	4.1 (2.4–10.0)	3.7 (1.5-8.2)	.15
CD34 ($\times 10^5/\text{kg}$) Median (range)	5.0 (2.3–10.7)	5.2 (1.1-15.4)	.44
CD3 ($\times 10^7/\text{kg}$) Median (range)	1.6 (0.9–3.6)	1.3 (0.2-3.1)	.01
Gender			.21
Male	11 (48%)	67 (62%)	
Patient CMV status			.09
Negative	14 (61%)	45 (42%)	
Positive	9 (39%)	63 (58%)	
HLA (donor #1+donor#2)			.09
4/6 + 4/6	3 (13%)	36 (33%)	
4/6 + 5/6	6 (26%)	29 (27%)	
4/6 + 6/6	0	3 (3%)	
5/6 + 5/6	8 (35%)	32 (30%)	
5/6 + 6/6	3 (13%)	4 (4%)	
6/6 + 6/6	3 (13%)	4 (4%)	
Diagnosis			.43
ALL	3 (13%)	14 (13%)	
AML	8 (35%)	34 (31%)	
CML	0	3 (3%)	
Other Leukemia	4 (17%)	6 (6%)	
MDS	0	3 (3%)	
NHL	7 (30%)	26 (24%)	
Hodgkin's Lymphoma	1 (4%)	19 (18%)	
Myeloproliferative Disease	0	3 (3%)	

Treg, regulatory T-cells; TNC, total nucleated cell dose; CMV, cytomegalovirus; HLA, human leukocyte antigen; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin's lymphoma.

Phase I treatment plan UCB-derived regulatory T Cells




Figure S1. Treatment strategy and dose escalation in the protocol




Figure S2. Proportion of CD4+CD127-FoxP3+ cells before and after CD25+ selection and at the end of the expansion culture period